New from BioWorld, Innovations in Biotechnology 2010: Visionary Start-Ups and Revolutionary Science, offers a landmark compilation of start-up companies and scientific advances paving the way in emerging biotech markets.
Shares in Genmab A/S slid more than 20 percent Monday on news that zalutumumab, an antibody-targeting epidermal growth factor receptor (EGFR), failed to reach the primary endpoint of a pivotal Phase III trial in head and neck cancer. (BioWorld Today)
Since nothing stirs the faithful quite so much as the perception of
persecution, the anti-science forces have been freshly energized by
The Lancet's retraction of a controversial 1998 paper suggesting a link between the MMR vaccine and autism. (BioPerspectives)
LONDON – Cellzome Ltd. signed its second big deal with GlaxoSmithKline plc, agreeing on a €475 million (US$644.3 million) collaboration to apply its epigenetics platform technology in the discovery of oral small-molecule drugs for treating immuno-inflammatory diseases. (BioWorld International)
